Get started
Author

Veronique R. De Jager

Observed names: V. de Jager, Veronique De Jager, Veronique R De Jager, Veronique R. de Jager, Veronique de Jager, de Jager, Veronique Rejean
Observed institution: Task Applied Science
ORCID: 0000-0001-6389-5575
Observed ORCID: 0000-0001-6389-5575
OpenAlex ID: A5057619790
Telacebec (Q203), a New Antituberculosis Agent
2020 · Veronique R. de Jager, Rodney Dawson, et al. · New England Journal of Medicine · 135
PDF
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1rifampicin
2021 · Lindsey H.M. te Brake, Veronique de Jager, et al. · European Respiratory Journal · 61
PDF
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
2024 · Andreas H. Diacon, Clifton E. Barry, et al. · Nature Medicine · 58
PDF
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
2021 · Yingda L. Xie, Veronique R. de Jager, et al. · Science Translational Medicine · 47
PDF
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
2020 · Andreas H. Diacon, Veronique R. De Jager, et al. · Antimicrobial Agents and Chemotherapy · 40
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30
PDF
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial
2022 · Veronique De Jager, Nikhil Gupte, et al. · American Journal of Respiratory and Critical Care Medicine · 30
Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
2018 · Elin M. Svensson, Jeannine du Bois, et al. · British Journal of Clinical Pharmacology · 30
PDF
Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond
2025 · Saskia Janssen, Caryn Upton, et al. · American Journal of Respiratory and Critical Care Medicine · 19
PDF
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial
2024 · Rodney Dawson, Andreas H Diacon, et al. · The Lancet Infectious Diseases · 18
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
2023 · Ralf Stemkens, Veronique de Jager, et al. · Antimicrobial Agents and Chemotherapy · 18
PDF
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
2023 · Rodney Dawson, Andreas H. Diacon, et al. · Antimicrobial Agents and Chemotherapy · 14
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial
2024 · Kamunkhwala Gausi, Elisa H. Ignatius, et al. · American Journal of Respiratory and Critical Care Medicine · 13
PDF
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial
2020 · Andreas Diacon, Sachiko Miyahara, et al. · The Lancet Microbe · 13
PDF
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials
2023 · Emmanuel Musisi, Adam Wyness, et al. · The Lancet Microbe · 11
PDF
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis
2022 · Kamunkhwala Gausi, Maxwell Chirehwa, et al. · Journal of Antimicrobial Chemotherapy · 10
PDF
Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies
2017 · Veronique De Jager, Lize van der Merwe, et al. · Antimicrobial Agents and Chemotherapy · 10
Optimizing β-Lactams against Tuberculosis
2020 · Veronique R. de Jager, Naadira Vanker, et al. · American Journal of Respiratory and Critical Care Medicine · 8
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5
PDF
Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers
2023 · Yuanxi Zou, Veronique de Jager, et al. · British Journal of Clinical Pharmacology · 5
PDF
BTZ-043 Shows Good Safety and Strong Bactericidal Activity in a Combined Phase1b/2a Study in Tuberculosis Patients
2023 · Norbert Heinrich, Veronique De Jager, et al. · SSRN Electronic Journal · 5
Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043
2025 · Simon E Koele, Norbert Heinrich, et al. · Journal of Antimicrobial Chemotherapy · 4
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
2021 · Ahmed A. Abulfathi, Veronique de Jager, et al. · Frontiers in Pharmacology · 3
PDF
Transrenal Mycobacterium tuberculosis DNA in pulmonary tuberculosis patients during the first 14 days of treatment
2023 · Irina Kontsevaya, Jan Heyckendorf, et al. · Microbiology Spectrum · 2
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
2023 · Saskia Janssen, Caryn M. Upton, et al. · Annals of the American Thoracic Society · 1
Works count: 35
Citation count: 591
H-index: 13
I10-index: 17
Year
Topic
Type